SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

SARS-CoV Related Products (1129)
Recombinant Proteins (194)

By Effects:	Inhibitors (1016) Degraders (8) Controls (5) Ligands (2) Modulators (2) Chemicals (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-151278A

SARS-CoV-2-IN-30 disodium	Inhibitor
SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC₅₀s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC₅₀ value of 6.9 μM.

HY-P5398

HR2-18	Inhibitor
HR2-18 is a biological active peptide， with inhibition of SARS-CoV penetration into cells.

HY-P991491

VIR-7229	Inhibitor
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-19195

TO-195 (hydrochlorid)	Inhibitor
TO-195 hydrochlorid is a protease inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). TO-195 hydrochlorid is promising for research of coronavirus disease 2019 (COVID-19).

HY-151474

SARS-CoV-2-IN-31	Inhibitor	99.09%
SARS-CoV-2-IN-31 is an effective COVID-19 inhibitor. SARS-CoV-2-IN-31 exhibits excellent to mild activity against various cancer cell lines with IC₅₀ values range from 28.84 to 38.36 μM. SARS-CoV-2-IN-31 can be used for the research of cancer.

HY-14588S

(rel)-Lopinavir-d₈	Inhibitor
(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 14.2 μM.

HY-178156

DHODH-IN-31	Inhibitor	99.55%
DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2.

HY-P10855

S1b3inL1	Inhibitor
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity.

HY-116977

Binifibrate	Inhibitor
Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia.

HY-168889

HRSV/hCoV-229E-IN-1	Inhibitor
HRSV/hCoV-229E-IN-1 (compound 8X) is a potent HRSV and hCoV-229E inhibitor with an IC₅₀ value of 2.1 µM for hCoV-229E. HRSV/hCoV-229E-IN-1 inhibits cell viability.

HY-155308

SARS-CoV-2-IN-61	Inhibitor
SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC₅₀ of 16 µM. SARS-CoV-2-IN-61 has antiviral activities.

HY-14768S

Favipiravir-¹³C¹⁵N	Inhibitor
Favipiravir-¹³C¹⁵N (T-705-¹³C¹⁵N) is ¹³C and ¹⁵N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-178137

SCR007	Inhibitor
SCR007 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR007 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR007 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR007 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR007 can be used for the study and prevention of enveloped virus pandemics.

HY-152589

Antiviral agent 25	Inhibitor
Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of SARS-CoV-2 3CL^pro. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CL^pro and SARS-CoV-2 PL^pro with IC₅₀ values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC₅₀ value of 7.249 µM.

HY-149868

SARS-CoV-2-IN-42	Inhibitor
SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of SARS-CoV-2 replication (EC₅₀: 0.4 μM). SARS-CoV-2-IN-42 has no obvious damage to the host cell.

HY-139892

XR8-69	Inhibitor
XR8-69 is a SARS-CoV-2 PLpro inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells.

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	Inhibitor
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection.

HY-149304

SARS-CoV-2-IN-40	Inhibitor
SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively.

HY-162151

SARS-CoV-2-IN-74	Inhibitor
SARS-CoV-2-IN-74 (compound 30) is a epoxide inhibitor, which inhibits cellular SARS-CoV-2 replication with an EC₆₈ of 5 μM. SARS-CoV-2-IN-74 can be used for the research of coronavirus.

HY-175461

AVI-4206	Inhibitor
AVI-4206 is a selective Mac1 inhibitor with an lC₅₀ of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of SARS-CoV-2 infection.

Name
Email *

	Sorry, but the email address you supplied was invalid.

SARS-CoV

SARS-CoV

SARS-CoV Related Products (1129)

Recombinant Proteins (194)

SARS-CoV Related Products (1129):